Skip to content

Glaukos GKOS Return on invested capital

Return on invested capital at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
20.6%+0.3pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
10.3%-2.0pp
AbbVie logo
AbbVieABBV
17.1%
Boston Scientific logo
Boston ScientificBSX
10.9%+4.0pp
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
2.6%-2.1pp
Exelixis logo
ExelixisEXEL
46.7%+10.4pp

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on trailing twelve months.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's return on invested capital?
Glaukos (GKOS) reported return on invested capital of -27.8% in Q1 2026.
How has Glaukos's return on invested capital changed year-over-year?
Glaukos's return on invested capital decreased by 69.6% year-over-year, from -16.4% to -27.8%.
What is the long-term trend for Glaukos's return on invested capital?
Over 5 years (2020 to 2025), Glaukos's return on invested capital has grown at a 9.5% compound annual growth rate (CAGR), from -18.5% to -29%.